Drug Profile
DCB F1
Alternative Names: DCB-F1Latest Information Update: 29 Aug 2023
Price :
$50
*
At a glance
- Originator Development Center for Biotechnology
- Class
- Mechanism of Action Interferon alpha modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 29 Aug 2023 Discontinued - Preclinical for Hepatitis C in Taiwan (unspecified route) (Development Center for Biotechnology website, August 2023)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Hepatitis-C in Taiwan
- 20 Jan 2016 DCB F1 is available for licensing as of 20 Jan 2016. http://www.dcb.org.tw/dcbe.aspx?pg=en-rd-pipeline